top of page

While inhibiting the Hedgehog signaling pathway has typically been used in oncology, San Diego based Endeavor BioMedicines has one they believe is well suited for fibrotic diseases like IPF

Jun 26

1 min read

John Hood, the successful biotech entrepreneur and Co-Founder and CEO of Endeavor, describes the biological hypothesis for Hedgehog inhibition in IPF and why he thinks ENV-101 is the right asset for it. It is currently in a phase 2b that will read towards the end of the year, and he believes the trial can show more than just a slowing of the disease.

https://vimeo.com/1204945051?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

See All

After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)

At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

Earlier this month, Agilent agreed to acquire Philadelphia based Proscia, a provider of digital pathology software for clinical and life-sciences customers, for $240M up front and up to $30M more

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more